Kindeva Appoints Daniel J. Speciale as the New Chief Financial Officer (CFO)

LOUIS, Mo. and WOODBURY, Minn., Mar. 31, 2025 – Kindeva, a global CDMO and drug delivery expert, has appointed Daniel J. Speciale as Chief Financial Officer (CFO) to strengthen its executive leadership team and drive financial strategy across the  organization. As Kindeva continues its growth trajectory, Mr. Speciale will oversee all financial  functions, ensuring strong fiscal management, strategic investments, and sustainable business  expansion.

“At a time of significant transformation and growth, having a strong financial leader is critical  to our success. Dan’s extensive expertise in corporate finance, investor relations, and strategic  planning will be invaluable as we continue to innovate and expand our global footprint. His  leadership will help drive financial excellence, optimize operational efficiency, and maximize  value for our stakeholders,” said Milton Boyer, CEO of Kindeva.

Mr. Speciale has nearly 20 years of financial leadership and deep healthcare and  pharmaceuticals. Most recently, Mr. Speciale served as Senior Vice President, Finance— Controller, and Chief Accounting Officer at Vantive, where he played a key role in establishing  financial strategy as the business separated from Baxter in a $3.8 billion sale to Carlyle. Previously, he held senior financial roles at Mallinckrodt, including Senior Vice President,  Finance and CFO of the Specialty Generics division, overseeing $800 million in annual revenue  while leading the controllership and investor relations functions. He began his career in the  assurance practice at PricewaterhouseCoopers LLP, and his expertise in financial leadership  across public and private companies makes him an asset to Kindeva’s growth.

Mr. Speciale holds a Bachelor of Science in Accountancy and a Master of Accounting Science  degree from the Gies College of Business at the University of Illinois Urbana-Champaign.

Commenting on his appointment, Mr. Speciale said, “I look forward to joining Kindeva at such  a dynamic time in its journey. Financial discipline, strategic investment, and operational  efficiency are critical in today’s evolving market. I look forward to joining the company and  working with the leadership team to drive sustainable growth and long-term success.”

Kindeva is a leading global CDMO with vast expertise in drug delivery devices. Learn more  about their services here.

KINDEVA CONFIDENTIAL

About Kindeva Drug Delivery

At Kindeva, our purpose is clear: manufacturing more tomorrows for patients worldwide. By investing in the highest quality facilities, finished-dose CDMO solutions and analytical capabilities, we provide strategic value that extends beyond manufacturing. Our global network of 10 manufacturing and R&D facilities offers exceptional capabilities, including expanded aseptic fill finish capacity and next-generation green propellant technologies. We leverage our sterile injectable, pulmonary, nasal and dermal expertise to help meet the demands of today and deliver the possibilities of tomorrow.